The United States market remained flat over the last week but has risen by 18% over the past year, with earnings forecasted to grow by 17% annually. In this environment, identifying stocks that are potentially priced below their estimated value can be an effective strategy for investors looking to capitalize on future growth opportunities.
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Zeta Global Holdings (ZETA) | $27.88 | $52.65 | 47.1% |
| United States Antimony (UAMY) | $5.20 | $9.88 | 47.4% |
| Symbotic (SYM) | $40.41 | $80.11 | 49.6% |
| Swarmer (SWMR) | $38.83 | $73.66 | 47.3% |
| Mobileye Global (MBLY) | $8.68 | $16.34 | 46.9% |
| Huntington Bancshares (HBAN) | $16.95 | $33.35 | 49.2% |
| FormFactor (FORM) | $107.72 | $208.49 | 48.3% |
| CVR Energy (CVI) | $37.89 | $74.25 | 49% |
| American Healthcare REIT (AHR) | $57.05 | $113.11 | 49.6% |
| Alerus Financial (ALRS) | $33.07 | $62.99 | 47.5% |
We'll examine a selection from our screener results.
Overview: Insight Enterprises, Inc. is a company that offers information technology solutions, including hardware, software, and services across the United States and various international regions, with a market capitalization of approximately $4.26 billion.
Operations: The company's revenue segments are comprised of $6.89 billion from North America, $1.41 billion from Europe, the Middle East, and Africa (EMEA), and $276.82 million from the Asia-Pacific (APAC) region.
Estimated Discount To Fair Value: 13.8%
Insight Enterprises appears undervalued, trading 13.8% below its estimated fair value of US$174.83. Despite high debt levels, earnings are projected to grow significantly at 23.3% annually, outpacing the broader US market's growth forecast. Recent buybacks and robust earnings reports highlight strong cash flow management, with Q2 revenue reaching US$2.4 billion and net income rising to US$77.57 million from a year ago, reflecting improved profitability despite slower revenue growth compared to the market.
Overview: American Healthcare REIT, Inc., a Maryland-based self-managed real estate investment trust, owns and operates a diversified portfolio of clinical healthcare properties across the U.S., U.K., and the Isle of Man with a market cap of $13.10 billion.
Operations: The company's revenue is primarily derived from Integrated Senior Health Campuses ($1.92 billion), Shop ($418.82 million), Outpatient Medical ($122.46 million), and Triple-net Leased Properties ($39.25 million).
Estimated Discount To Fair Value: 49.6%
American Healthcare REIT, trading at US$57.05, is significantly undervalued relative to its estimated future cash flow value of US$113.11. Despite recent shareholder dilution and substantial insider selling, earnings are expected to grow 28% annually, surpassing the US market's average growth rate. The company raised its full-year earnings guidance following a successful follow-on equity offering of US$712 million, highlighting robust cash flow potential despite slower revenue growth projections compared to peers.
Overview: Bloom Energy Corporation designs, manufactures, sells, and installs solid oxide fuel cell systems for on-site power generation globally and has a market cap of approximately $60.09 billion.
Operations: The company generates revenue primarily from its electric equipment segment, which accounted for $3.11 billion.
Estimated Discount To Fair Value: 40.1%
Bloom Energy, with a current trading price of US$217.45, is undervalued compared to its estimated future cash flow value of US$362.82. Despite recent insider selling and shareholder dilution, the company’s earnings are projected to grow at 42.46% annually, outpacing the broader market's growth rate. Recent product innovations like Power Connect enhance deployment efficiency, while expanded partnerships bolster its strategic positioning in AI infrastructure development despite legal challenges regarding supply chain disclosures.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com